FGFR2 and neoplasm: In addition to the FGFR2-SH3GLB1 fusion, the first and second tumor-normal DNA analyses showed a likely oncogenic stop-gain variant in TSC1 together with a heterozygous deletion of the unaffected allele in the liver biopsy (Supplementary Figure S2).